Core Insights - Cytek Biosciences, Inc. has been recognized as one of America's Growth Leaders of 2026 by TIME in partnership with Statista, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][14]. Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver innovative tools for laboratories [7]. - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [7]. Financial Performance - The inclusion in TIME's list signifies Cytek's strong financial foundation and sustained business expansion, reflecting its ability to deliver long-term value [2][5]. - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, indicating their significant impact on global research [4]. Innovation and Technology - Cytek's mission is to make high-parameter cell analysis more accessible and cost-effective, addressing urgent challenges in health and science, such as cancer research and vaccine development [3]. - The company's FSP technology sets a new standard in flow cytometry, enhancing the precision and sensitivity of cell analysis [3][7]. Market Position - Being named to the Growth Leaders list places Cytek among an elite group of companies demonstrating resilience and a forward-looking approach in a dynamic market [5].

Core Insights - Cytek Biosciences, Inc. has been recognized in TIME's 2026 list of America's Growth Leaders, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][5] - The inclusion in this list signifies Cytek's strong financial foundation and sustained business expansion, particularly in delivering innovative cell analysis solutions [2][5] Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to enhance the precision and sensitivity of cell analysis [6] - The company aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, addressing urgent challenges in health and scientific research [3][4] Industry Impact - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant impact on global research [4] - The company's innovations support advancements in cancer research, cell and gene therapies, vaccine development, and responses to emerging diseases [3][4]

Core Insights - Cytek Biosciences reported a total revenue of $52.3 million for Q3 2025, reflecting a 2% increase compared to Q3 2024, driven by growth in the US, APAC, and other regions, despite a decline in EMEA [4][10] - The company experienced a GAAP gross profit of $27.6 million, a 5% decrease from the previous year, with a gross profit margin of 53% compared to 56% in Q3 2024 [5][10] - Operating expenses rose to $36.7 million, a 10% increase year-over-year, primarily due to a significant rise in general and administrative expenses [6][8] - The company reported a loss from operations of $9.2 million, compared to a loss of $4.2 million in Q3 2024, and a net loss of $5.5 million compared to a net income of $0.9 million in the same period last year [9][10] - Cytek's total recurring revenue grew by 19% year-over-year, indicating strong performance in service and reagent revenues [10] - The company reaffirmed its 2025 revenue guidance, expecting total revenue to be in the range of $196 million to $205 million, representing a growth of -2% to +2% over 2024 [12] Financial Performance - Total revenue for Q3 2025 was $52.3 million, up from $51.5 million in Q3 2024 [4][10] - GAAP gross profit was $27.6 million, down from $29.0 million in Q3 2024, with a gross profit margin of 53% [5][10] - Operating expenses were $36.7 million, with R&D expenses at $9.0 million (down 9%) and sales and marketing expenses at $11.7 million (down 6%) [6][7] - The net loss for Q3 2025 was $5.5 million, compared to a net income of $0.9 million in Q3 2024 [9][10] Strategic Developments - The installed base of Cytek instruments expanded to 3,456, with 161 new units added in Q3 2025 [10] - The company expanded its European headquarters in Amsterdam, increasing its footprint by over 40% [10] - Cytek's revenue from biotechnology, pharmaceutical, and clinical research organization customers grew by 14% year-over-year [10]

Core Insights - Cytek Biosciences, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close, followed by a conference call to discuss the results and outlook [1] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2] - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents and software, providing a comprehensive suite of solutions for customers [2] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2] Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3] Information Distribution - The company utilizes multiple channels, including its website, LinkedIn, and X account, to disseminate material information and comply with disclosure obligations under Regulation FD [4]

Core Insights - Cytek Biosciences has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District, reflecting its commitment to the EMEA region and enhancing service for customers [1][4] - The new site has increased the company's footprint by over 40% and includes a dedicated customer service and training center, providing hands-on training for researchers [2] - The success of Cytek's reagent business is a major driver for this expansion, with the company transitioning warehouse operations in-house to improve operational efficiency and quality control [3] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5] - The company's product offerings include various systems and technologies designed to enhance multiplexing capabilities and provide comprehensive solutions for researchers [5] - Cytek's products are primarily for research use, with certain systems available for clinical use in specific regions [6] Strategic Importance - Europe is identified as a key region for Cytek's global growth, and the new Amsterdam facility is expected to enhance the company's capabilities in delivering solutions and services across the EMEA region [4][15] - The expansion aims to support scientific understanding and accelerate data-driven decision-making, fostering innovation within the industry [4]

Core Insights - Cytek Biosciences, a leader in spectral flow cytometry, is set to showcase its advanced solutions at two major industry events, emphasizing the growing demand for deeper cellular insights in cancer research and diagnostics [1][4] Company Overview - Cytek Biosciences specializes in high-resolution, high-content, and high-sensitivity cell analysis tools, utilizing its patented Full Spectrum Profiling™ (FSP) technology [8] - The company's FSP systems have been referenced in over 2,800 peer-reviewed publications, indicating widespread acceptance and application in the research community [2] Technology and Innovation - Cytek's Full Spectrum Profiling™ technology allows for the profiling of more than 40 markers in a single tube, significantly enhancing efficiency and reducing analysis time [7] - The integration of spectral flow cytometry with machine learning is being explored to simplify data analysis and reduce technician workload, as demonstrated in workshops at upcoming conferences [4][6] Industry Events - The European Society for Clinical Cell Analysis (ESCCA) 2025 Conference will take place from September 17 to September 20, 2025, in Montpellier, France, focusing on clinical applications in various fields [3] - The ICCS Annual Meeting & Course will be held from September 28 to September 30, 2025, in Philadelphia, bringing together professionals to advance knowledge in clinical cytometry [5] Leadership and Expertise - Dr. Wenbin Jiang, CEO of Cytek, highlighted the advantages of spectral flow cytometry in enabling laboratories to achieve more with less, thereby allowing scientists to focus on high-skill tasks [7] - Workshops led by experts like Dr. Joseph C. Lownik and Dr. Paul K. Wallace will present innovative approaches to using spectral flow cytometry for accurate diagnosis of leukemia and lymphoma [4][6]

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q2 2025 on August 6, 2025, followed by a conference call to discuss the results and business outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2]. - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents, software, and services [2]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3]. Information Distribution - The company utilizes its website, LinkedIn, and X (formerly Twitter) for distributing material information and compliance with disclosure obligations under Regulation FD [4].

Core Viewpoint - Cytek Biosciences, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its active engagement in the healthcare investment community [1]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that specializes in high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [3]. - The company offers a comprehensive suite of products including the Cytek Aurora™, Northern Lights™, and Cytek Orion™ systems, as well as flow cytometers and imaging products under the Amnis and Guava brands [3]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3]. Upcoming Events - Cytek management is scheduled for a fireside chat on June 11 at 11:40 a.m. Pacific Time, which will be accessible via a live and archived webcast on the company's website [2].

Core Insights - Cytek Biosciences reported a total revenue of $41.5 million for Q1 2025, reflecting a 7.6% decrease compared to Q1 2024, primarily due to a slowdown in product sales in the US and EMEA regions, although this was partially offset by growth in the APAC region and strong service revenue globally [4][8] - The company experienced a gross profit of $20.2 million in Q1 2025, which is a 12% decrease from the previous year, resulting in a GAAP gross profit margin of 49% compared to 51% in Q1 2024 [5][20] - Operating expenses increased by 4.1% to $35.1 million, with general and administrative expenses rising significantly from $11.4 million in Q1 2024 to $12.9 million in Q1 2025 [6][7] - The net loss for Q1 2025 was $11.4 million, compared to a net loss of $6.2 million in Q1 2024, indicating a worsening financial position [7][20] - Cytek's cash and marketable securities totaled $265.6 million as of March 31, 2025, down from $277.9 million at the end of 2024, despite share repurchases of $10.6 million during the quarter [9][20] - The company has revised its full-year 2025 revenue guidance to a range of $196 million to $210 million, which represents a potential decline of 2% to growth of 5% compared to 2024 [10] Financial Performance - Total revenue for Q1 2025 was $41.5 million, with product revenue at $28.1 million and service revenue at $13.3 million [20] - Gross profit for the quarter was $20.2 million, leading to a GAAP gross margin of 49% [5][20] - Operating expenses were $35.1 million, with research and development expenses at $9.7 million and sales and marketing expenses remaining flat at $12.5 million [6][20] - The adjusted EBITDA loss for Q1 2025 was $3.3 million, compared to a loss of $0.7 million in Q1 2024 [8][20] Strategic Developments - Cytek expanded its installed base to 3,149 instruments, adding 115 units in Q1 2025, and commenced operations in Singapore to enhance manufacturing capacity [8] - The company launched the Cytek Muse Micro instrument, aimed at providing an affordable option for simplified flow cytometry [8] - Cytek repurchased $10.6 million of its common stock during the first quarter, indicating a commitment to returning value to shareholders [8]

Core Insights - Cytek Biosciences is committed to advancing cell analysis through its patented Full Spectrum Profiling™ (FSP) technology, which will be showcased at key industry events such as CYTO 2025 and IMMUNOLOGY2025 [1][2][5] Company Overview - Cytek Biosciences, Inc. (Nasdaq: CTKB) is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity tools [6][7] - The company’s FSP technology enhances multiplexing capabilities with precision and sensitivity, positioning it as a pioneer in spectral flow cytometry [6][2] Industry Events - At IMMUNOLOGY2025, Cytek will present its complete cell analysis solutions, including instruments, reagents, and software, aimed at advancing research and discovery [3][4] - The company will also host a workshop on in-depth characterization of mouse immune responses during the event [4] - CYTO 2025 will feature Cytek as a Platinum sponsor, where it will showcase technology designed to accelerate scientific discovery [4][5] Strategic Goals - Cytek aims to make flow cytometry technology more accessible and scalable, unlocking new opportunities in high-growth areas such as immunology, oncology, and cell therapy [2][5] - The company emphasizes its commitment to delivering innovative and flexible solutions to empower researchers and accelerate breakthroughs in scientific advancement [5]